Drug Price Trends for ATOVAQUONE-PROGUANIL

Average Pharmacy Cost for ATOVAQUONE-PROGUANIL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ATOVAQUONE-PROGUANIL 62.5-25	68462-0402-01	1.22591	EACH	2024-12-18
ATOVAQUONE-PROGUANIL 250-100 MG TABLET	00378-4162-01	1.56337	EACH	2024-12-18
ATOVAQUONE-PROGUANIL 250-100 MG TABLET	66993-0060-02	1.56337	EACH	2024-12-18
ATOVAQUONE-PROGUANIL 250-100 MG TABLET	68001-0245-00	1.56337	EACH	2024-12-18

Atovaquone and Proguanil Market Analysis and Price Projections

Market Overview

The global Atovaquone and Proguanil market is poised for significant growth, driven by the increasing incidence of malaria and the need for effective antimalarial treatments. Here is a comprehensive analysis of the market, including its current state, future projections, and key factors influencing its growth.

Current Market Size and Revenue

As of 2024, the global Atovaquone and Proguanil market size is estimated to be USD 185.6 million. This figure is dominated by North America, which accounts for more than 40% of the global revenue, with a market size of USD 74.24 million[1].

Regional Market Analysis

North America

North America is the largest market for Atovaquone and Proguanil, driven by increased travel to malaria-endemic areas and a strong focus on malaria prevention. The region's robust healthcare infrastructure and high disposable incomes contribute significantly to the demand for these antimalarial medications. The market in North America is expected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031[1].

Europe

Europe is emerging as the fastest-growing region in the Atovaquone and Proguanil market. This growth is attributed to increasing global travel to malaria-prone regions and a heightened emphasis on malaria prevention measures. Europe's strong healthcare systems and focus on travel medicine are key drivers of this growth[1].

Asia Pacific

The Asia Pacific region holds around 23% of the global revenue, with a market size of USD 42.6 million in 2024. This region is expected to grow at a CAGR of 13.5% from 2024 to 2031, driven by the rising incidence of malaria and improving healthcare infrastructure[1].

Latin America and Middle East & Africa

Latin America accounts for more than 5% of the global revenue, with a market size of USD 9.28 million in 2024, and is expected to grow at a CAGR of 10.9% from 2024 to 2031. The Middle East and Africa hold around 2% of the global revenue, with a market size of USD 3.71 million in 2024, and are expected to grow at a CAGR of 11.2% during the same period[1].

Growth Drivers

Increasing Incidence of Malaria

The global incidence of malaria is a significant driver of the Atovaquone and Proguanil market. According to the WHO, there were an estimated 249 million malaria cases and 608,000 fatalities in 85 countries in 2022. This rising disease burden is expected to boost the demand for effective antimalarial treatments[3].

Travel and Tourism

Increased travel to malaria-endemic areas is another key factor driving the market. As travel restrictions ease post-pandemic, the demand for reliable antimalarial medications like Atovaquone and Proguanil is expected to rise[1].

Healthcare Infrastructure and Government Initiatives

Strong healthcare infrastructure in regions like North America and Europe, along with government initiatives and investments in malaria prevention and treatment, are also driving the market growth. For example, the Global Health Innovative Technology Fund (GHIT Fund) of Japan has invested in research projects to develop advanced antimalarial drugs[3].

Challenges

Drug Resistance and Supply Chain Disruptions

The market faces challenges such as drug resistance, which can limit the effectiveness of antimalarial medications. Additionally, supply chain disruptions and logistical issues, particularly highlighted during the COVID-19 pandemic, can affect the availability and distribution of these drugs[1].

Higher R&D Costs and Limited Funding

High research and development costs and limited funding for antimalarial drug development can also hinder market growth. These factors can restrict innovation and the widespread access to effective treatments, especially in regions with inadequate healthcare infrastructure[3].

Price Projections

Current Pricing

The current price for Atovaquone and Proguanil oral tablets varies based on the quantity. For example, a 14-tablet pack can cost around $39.51, with a per-unit price of $2.82[2].

Future Market Size and Growth

The global Atovaquone and Proguanil market is projected to expand significantly. By 2031, the market is expected to reach USD 397.65 million, growing at a CAGR of 11.50% from 2024 to 2031[1].

Key Players

The market is dominated by several key players, including GlaxoSmithKline (GSK), Glenmark, Mylan Pharmaceuticals, and Hetero. These companies are focusing on strategies such as partnerships, new product launches, and production capacity expansions to maintain their competitive edge[5].

Applications

Atovaquone and Proguanil are primarily used for both adult and pediatric populations. The treatment segment is expected to capture a significant share of the market, driven by the increasing need for effective malaria treatments[5].

Impact of COVID-19

The COVID-19 pandemic had a multifaceted impact on the Atovaquone and Proguanil market. While travel restrictions initially reduced demand, the ongoing need for malaria prevention and treatment in endemic areas persisted. The pandemic underscored the importance of robust healthcare systems capable of addressing infectious diseases, including malaria. As vaccination efforts progress and travel resumes, the market is anticipated to rebound[1].

"The COVID-19 pandemic has had a multifaceted impact on the market for atovaquone-proguanil... However, the pandemic also underscored the significance of maintaining robust healthcare structures able to address infectious diseases, including malaria." - Cognitive Market Research[1]

Key Takeaways

• Market Size and Growth: The global Atovaquone and Proguanil market was valued at USD 185.6 million in 2024 and is expected to grow to USD 397.65 million by 2031 at a CAGR of 11.50%.
• Regional Dominance: North America is the largest market, followed by Europe, which is the fastest-growing region.
• Growth Drivers: Increasing incidence of malaria, travel to endemic areas, and strong healthcare infrastructure are key drivers.
• Challenges: Drug resistance, supply chain disruptions, and high R&D costs are significant challenges.
• Key Players: GSK, Glenmark, Mylan Pharmaceuticals, and Hetero are major players in the market.

FAQs

What is the current global market size for Atovaquone and Proguanil?

The global Atovaquone and Proguanil market size was estimated at USD 185.6 million in 2024[1].

Which region dominates the Atovaquone and Proguanil market?

North America dominates the market, accounting for more than 40% of the global revenue[1].

What is the expected CAGR for the Atovaquone and Proguanil market from 2024 to 2031?

The market is expected to grow at a CAGR of 11.50% from 2024 to 2031[1].

What are the main challenges facing the Atovaquone and Proguanil market?

The main challenges include drug resistance, supply chain disruptions, and high R&D costs[1][3].

Who are the key players in the Atovaquone and Proguanil market?

Key players include GlaxoSmithKline (GSK), Glenmark, Mylan Pharmaceuticals, and Hetero[5].

How has the COVID-19 pandemic impacted the Atovaquone and Proguanil market?

The pandemic initially reduced demand due to travel restrictions but underscored the importance of robust healthcare systems for infectious diseases, including malaria[1].

Sources

1. Cognitive Market Research, "Atovaquone and Proguanil Market Report 2024 (Global Edition)".
2. Drugs.com, "Atovaquone/proguanil Prices, Coupons, Copay Cards & Patient Assistance Programs".
3. GMI Insights, "Antimalarial Drugs Market Size | Growth Forecasts Report, 2032".
4. Market Research Intellect, "Global Atovaquone and Proguanil Market Size | Share | Scope | Trend".
5. Valuates Reports, "Atovaquone and Proguanil - Market Size".